logo
logo
logo
logo
  • News
  • Approach
  • ESG
  • Portfolio
  • Team
  • Tech Investments
  • Contact

Wellington Partners participates in $53 Million Series B financing at ImCheck

4. December 2019
|In Portfolio News
|By eazee-designstudio

Wellington Partners participates in $53 Million Series B financing at ImCheck

4. December 2019
|In Portfolio News
|By eazee-designstudio

ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (γδ)T cells in a range of cancer indications and a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases, announced today the closing of a $53 million (€48 million) Series B financing round. The proceeds of the Series B will be used to fund the initial clinical trial for ImCheck’s first-in-class monoclonal antibody ICT01, to further expand the company’s broad pipeline of immunomodulators targeting the butyrophilins super-family and to bring additional immuno-oncology antibody programs into the clinic.

  • Prev
  • Next

© 2022 Wellington Partners. All rights reserved  |  Imprint  |  Privacy Policy | SFDR Disclosures | PRIIPS

Privacy Preference Center

Privacy Preferences